· Published by Health Canada · Official notice
This is duplicated text of a letter from Eli Lilly Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
October 21, 2011
Subject: Association of STRATTERA (atomoxetine) with Increased Blood Pressure and Increased Heart Rate
Dear Health Care Professional,
Eli Lilly Canada Inc. in collaboration with Health Canada would like to inform you of important information from clinical studies regarding the risk of increased blood pressure and increased heart rate with the use of STRATTERA (atomoxetine). Atomoxetine is a selective norepinephrine reuptake inhibitor indicated for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults.
Atomoxetine can increase heart rate and blood pressure. Please be aware of the following recommendations:
A recent analysis of combined data from Eli Lilly sponsored controlled and uncontrolled clinical trials has indicated that in 8,417 pediatric patients treated with atomoxetine, approximately 25% experienced an increase in blood pressure of 10 mmHg and 5-8% an increase of 20 mmHg while heart rate increased by 10 bpm in 33% of patients and by 20 bpm in 12% of patients. These increases could represent a risk for some patients. Increases in blood pressure and heart rate have been observed in similar proportion of adult ADHD patients.
This Dear Health Professional Letter (DHPL) is also posted on Advisories, Warnings and Recalls for the Public - 2011 and on Eli Lilly Canada.
The Canadian Product Monograph for STRATTERA has recently been revised to include these important new safety findings. A copy of the most up-to-date Product Monograph can be found at: Drug Product Database Online Query
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious increases in blood pressure or heart rate or other serious or unexpected adverse reactions in patients receiving STRATTERA should be reported to Eli Lilly Canada Inc. or Health Canada.
Eli Lilly Canada Inc.
Toronto, Ontario
1-888-545-5972
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
Sincerely,
original signed by
Loren D. Grossman, MD, FRCPC, FACP
Vice-President, Research and Development
Eli Lilly Canada Inc.